TSBX stock icon

Turnstone Biologics
TSBX

$2.51
3.47%

Market Cap: 58.1M

 

About: Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Employees: 82

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

138% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 8

11% more funds holding

Funds holding: 35 [Q4 2023] → 39 (+4) [Q1 2024]

6% more capital invested

Capital invested by funds: $30.8M [Q4 2023] → $32.6M (+$1.8M) [Q1 2024]

1.4% more ownership

Funds ownership: 52.51% [Q4 2023] → 53.91% (+1.4%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for TSBX.

Financial journalist opinion